Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
NCT07394244Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab, becotatug vedotin in cutaneous squamous cell carcinoma (cSCC), sponsored by Fudan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pucotenlimabbecotatug vedotin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT07394244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394244.